New York, NY -- (SBWIRE) -- 01/06/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Baxano Surgical Inc (NASDAQ:BAXS), PDL BioPharma Inc (NASDAQ:PDLI), Antares Pharma Inc (NASDAQ:ATRS), DragonWave, Inc.(USA) (NASDAQ:DRWI)
Baxano Surgical Inc (NASDAQ:BAXS) showed a volume of 1.71 million shares by the end of last trade whereas the average volume of the stock remained 405,947.00 shares. The stock opened the session at $1.05 but then moved to $1.11. At that price, the stock showed a positive performance of 7.75%. Baxano Surgical Inc, formerly TranS1 Inc., is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region. It develops its pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising important surrounding soft tissue, nerves and bone structures.
Will BAXS Continue To Move Higher? Find Out Here
PDL BioPharma Inc (NASDAQ:PDLI) opened the session at $8.62 and closed the session at $8.61. The stock showed a positive performance of 0.82% in previous trading session. Traded with volume of 1.68 million shares in the prior session and the average volume of the stock remained 2.73 million shares. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.
For How Long PDLI will fight for Profitability? Read This Trend Analysis report
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.57 and closed the session at $4.56. The stock showed a positive performance of 0.44% in previous trading session. Traded with volume of 1.67 million shares in the prior session and the average volume of the stock remained 1.10 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.
Why Should Investors Buy ATRS After The Recent Gain? Just Go Here and Find Out
DragonWave, Inc.(USA) (NASDAQ:DRWI) the stock advanced 8.10% and finished the session at $1.53. Traded with volume of 1.65 million shares in the prior session and the average volume of the stock remained 899,663.00 shares. The beta of the stock remained 1.46. DragonWave Inc. (DragonWave) is in the business of developing broadband wireless backhaul and pseudowire equipment. The Company is a provider of wireless Ethernet equipment used in Internet protocol (IP) networks. DragonWave designs, develops, markets and sells carrier-grade microwave radio frequency networking equipment (referred to as links), that wirelessly transmit broadband voice, video and other data between two points.
Will DRWI Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)